EXACT Sciences — Q3 2023 Earnings Presentation
16 slides from EXACT Sciences's earnings presentation, Nov 1, 2023
Slide 1: Third-quarter 2023 earnings call
We aim to help eradicate cancer by preventing it, detecting it earlier, and guiding its treatment. Third-quarter 2023 earnings call November 1, 2023 EXACT SCIENCES 1
Slide 2: Safe harbor and non-GAAP disclosures
Safe harbor and non-GAAP disclosures This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are sub
Slide 3: Delivering innovative tests that help eradicate cancer
Delivering innovative tests that help eradicate cancer by preventing it, detecting it earlier, and guiding its treatment OUR TEAM OUR FLAGSHIP TESTS Q3 RESULTS 500 1M+ Record total revenue of $628M, 23% core revenue growth R&D team members people tested in 3Q23 1,200 Expands Oncotype DX impact with
Slide 4: Core revenue grew 23% in 3Q23
Core revenue grew 23% in 3Q23 Core revenue Screening revenue Precision Oncology core revenue $625M +23% $472M $506M +31% $361M $145M $153M +5% 3Q22 3Q23 3Q22 3Q23 3Q22 3Q23 Please refer to our third-quarter 2023 earnings release at exactsciences.com for discussion of non-GAAP financial measures and
Slide 5: Updated 2023 guidance
Updated 2023 guidance Prior guidance November 1 update ∆ at midpoint Total revenue $2.441 - 2.466B $2.476 - 2.486B +$28M Screening $1.820 - 1.835B $1.848 - 1.853B +$23M Precision Oncology $615 - 625M $622 - 627M +$5M COVID testing $6M $6M - Adj. EBITDA $170 - 180M $195 - 205M +$25M CapEx ~$120M ~$12
Slide 6: Cologuard is having a meaningful impact
Cologuard® is having a meaningful impact and becoming more deeply ingrained in clinical practice 15 13M 13 Cumulative completed 11 Cologuard tests 13 million 10 million 9 completed tests 7 5 3 1 -1 2015 2016 2017 2018 2019 2020 2021 2022 2023 November 1, 2023 EXACT SCIENCES 6
Slide 7: Expanding Oncotype DX impact globally and introducing new genomic tools
Expanding Oncotype DX® impact globally and introducing new genomic tools HEREDITARY EARLY-STAGE RECURRENCE LATE-STAGE TESTING THERAPY TESTING THERAPY (tissue) Resolution (liquid) Bioscience EXACT SCIENCES 7
Slide 8: A new standard in non-invasive screening
BLUE-C DeeP-C (n=20,176) (n=9,989) A new standard in Specificity including no findings 91% 87% non-invasive screening Specificity including 93% 90% non-advanced findings Cancer 94% 92% next-generation sensitivity Curable-stage 93% 93% cancer sensitivity High-grade dysplasia 75% 69% sensitivity Advan
Slide 9: We aim to help eradicate cancer by preventing it
We aim to help eradicate cancer by preventing it, detecting it earlier, and guiding its treatment. EXACT SCIENCES 9
Slide 10: Exact Sciences
EXACT SCIENCES 10
Slide 11: Condensed Consolidated Statements of Operations
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Operations (Amounts in thousands, except per share data) Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Revenue $ 628,338 $ 523,073 $ 1,852,881 $ 1,531,284 O
Slide 12: Condensed Consolidated Balance Sheets
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Balance Sheets (Amounts in thousands) September 30, December 31, 2023 2022 Assets Cash and cash equivalents $ 594,612 $ 242,493 Marketable securities 139,794 389,564 Accounts receivable, net 199,403 158,043 In
Slide 13: Reconciliation of Core Revenue
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Reconciliation of Core Revenue (Amounts in thousands) GAAP Three Months Ended September 30, 2023 2022 % Change Screening $ 472,013 $ 360,759 31 % Precision Oncology 156,325 151,443 3 % COVID-19 Testing — 10,871 (100) % Total $ 628,3
Slide 14: Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations (Amounts in thousands) Three Months Ended September Nine Months Ended September 30, 30, 2023 2022 2023 2022 Revenue $ 628,338 $ 523,073 $ 1,852,881 $ 1,531,284 Cost of
Slide 15: EBITDA and Adjusted EBITDA Reconciliations
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information EBITDA and Adjusted EBITDA Reconciliations (Amounts in thousands) Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2023 2022 2023 2022 Net income (loss) $ 794 $ (148,761) $ (154,383) $ (495,761) Intere
Slide 16: Statements of Cash Flows and Reconciliation of Free Cash Flow
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow (Amounts in thousands) Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2023 2022 2023 2022 Net cash provided by (us